8.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
BioCryst Pharmaceuticals 2025 Q2 Earnings Record Net Income Surges 140% - AInvest
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Awards Massive Stock Package: 10 New Hires Get 126,450 Shares in Options and RSUs - Stock Titan
BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves - TipRanks
BioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances - MSN
BioCryst’s Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy Rating - TipRanks
BioCryst (BCRX) Q2 Revenue Jumps 50% - AOL.com
BioCryst Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
BioCryst: Q2 Earnings Snapshot - New Haven Register
BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... - Yahoo Finance
BioCryst Pharmaceuticals Reports Record Q2 2025 Results - TipRanks
BioCryst Pharmaceuticals: A Strategic Blueprint for $1 Billion in ORLADEYO Revenue by 2027 - AInvest
BioCryst Pharmaceuticals' Q2 2025: Unpacking Contradictions in ORLADEYO Demand, Market Share, and Financial Metrics - AInvest
BioCryst Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level - Stocktwits
BioCryst Pharmaceuticals Soars 15.35% on Strong Earnings - AInvest
Earnings call transcript: BioCryst Q2 2025 sees strong earnings beat, shares surge - Investing.com
BioCryst Pharmaceuticals Reports Impressive Q2 EarningsNews and Statistics - IndexBox
BioCryst Keeps Momentum With Strong ORLADEYO Sales And Rising Profits - Finimize
BioCryst Pharma soars 6.4% as Q2 results crush expectations - Investing.com
BioCryst Q2 2025 slides: ORLADEYO demand surges, profitability accelerates By Investing.com - Investing.com Canada
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
BioCryst Pharmaceuticals: A High-Conviction Biotech Play with a Defensible Moat in Rare Disease Innovation - AInvest
BioCryst Reports Strong Q2 2025 Financial Performance - TipRanks
Is This the Dip to Buy in BioCryst Pharmaceuticals Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
BioCryst (BCRX) Q2 Revenue Jumps 50% - The Motley Fool
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Is it the right time to buy BioCryst Pharmaceuticals Inc. stockTrack high-yield stocks before they peak - Jammu Links News
What is the dividend policy of BioCryst Pharmaceuticals Inc. stockDiscover undervalued stocks before they soar - Jammu Links News
BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastTrack top-performing stocks effortlessly - Jammu Links News
How strong is BioCryst Pharmaceuticals Inc. company’s balance sheetCapitalize on emerging industry trends - Jammu Links News
What makes BioCryst Pharmaceuticals Inc. stock price move sharplyMaximize gains with expert analysis - Jammu Links News
How does BioCryst Pharmaceuticals Inc. compare to its industry peersDiscover breakthrough stocks before the crowd - Jammu Links News
Is BioCryst Pharmaceuticals Inc. a growth stock or a value stockInvest confidently with professional market insights - Jammu Links News
When is BioCryst Pharmaceuticals Inc. stock expected to show significant growthStrong return on investment - Jammu Links News
How volatile is BioCryst Pharmaceuticals Inc. stock compared to the marketBuild wealth steadily with smart stock selection - Jammu Links News
What catalysts could drive BioCryst Pharmaceuticals Inc. stock higher in 2025Unlock expert stock analysis and alerts - Jammu Links News
What are the technical indicators suggesting about BioCryst Pharmaceuticals Inc.Double or triple returns - Jammu Links News
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO - MSN
Is BioCryst Pharmaceuticals Inc. a good long term investmentFree Stock Market Query - Jammu Links News
Is BioCryst Pharmaceuticals Inc. stock overvalued or undervaluedFind the best stocks for sustainable growth - Jammu Links News
BioCryst Pharmaceuticals Q2 2025 Earnings Preview: Revenue Expected to Rise 37% YoY - AInvest
BioCryst Announces New President Amid Leadership Change - The Globe and Mail
Healthcare Triangle, Inc. shares fall 3.23% after-hours as BioCryst Pharmaceuticals announces CEO transition. - AInvest
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse - GlobeNewswire
BioCryst Pharmaceuticals' Leadership Transition: Strategic CEO Appointment and Its Impact on Pipeline Execution and Shareholder Value Creation - AInvest
BioCryst Pharmaceuticals Before Q2 Earnings: How To Play The Stock - Barchart.com
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock - The Globe and Mail
BioCryst (BCRX) Announces Leadership Transition Plan - GuruFocus
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Ch - GuruFocus
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):